ADMA Biologics reported third quarter 2026 total revenue of $141.1 million, up 5% from a year earlier, and GAAP net income of $49.9 million, up 37%. The company reiterated its FY2026 revenue outlook of at least $530 million and raised its minimum expectations for Adjusted Net Income and Adjusted EBITDA. BIVIGAM revenue fell from the prior-year quarter, a trend the company says showed signs of stabilizing.
Q3 2026 ASCENIV revenue was $124.7 million, up 31% year-over-year; BIVIGAM revenue was $15.4 million, down from $23.8 million a year earlier.
GAAP net income was $49.9 million, or $0.22 basic EPS, compared with $36.4 million and $0.15 in the prior-year quarter.
FY2026 outlook: total revenue at least $530 million (reiterated), Adjusted Net Income at least $180 million, and Adjusted EBITDA at least $275 million (both raised).
The company repurchased 2.7 million shares in the third quarter and is on track for a $200 million or more 2026 buyback target.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From ADMA Biologics, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$510.17M
+19.6%
$0.60
-25.9%
28.8%
FY2024
$426.45M
+65.2%
$0.81
—
46.4%
FY2023
$258.21M
+67.6%
$-0.13
—
-10.9%
FY2022
$154.08M
+90.4%
$-0.33
—
-42.8%
FY2021
$80.94M
+91.7%
$-0.51
—
-88.5%
Frequently asked questions
When is ADMA Biologics's next earnings date?
ADMA Biologics has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did ADMA Biologics earn last quarter?
For the quarter ended Sep 2026, ADMA Biologics reported diluted EPS of $0.22 (+46.7% year over year) on revenue of $141.10M (+5.1%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.